Literature DB >> 17321017

Rotavirus vaccines--an update.

Penelope H Dennehy1.   

Abstract

Rotavirus infection is the most common cause of severe diarrhea disease in infants and young children worldwide and continues to have a major global impact on childhood morbidity and mortality. Vaccination is the only control measure likely to have a significant impact on the incidence of severe dehydrating rotavirus disease. Rotavirus disease prevention efforts suffered a severe setback in 1999 with the withdrawal of the RRV-TV vaccine less than a year after its introduction. Several new rotavirus vaccines have been developed and have proven to be safe and efficacious. These new safe and effective rotavirus vaccines offer the best hope of reducing the toll of acute rotavirus gastroenteritis in both developed and developing countries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17321017     DOI: 10.1016/j.vaccine.2007.01.102

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Advances in vaccine technology and their impact on managed care.

Authors:  Jonathan A McCullers; Jeffrey D Dunn
Journal:  P T       Date:  2008-01

2.  Novel triacsin C analogs as potential antivirals against rotavirus infections.

Authors:  Yunjeong Kim; David George; Allan M Prior; Keshar Prasain; Shuanghong Hao; Duy D Le; Duy H Hua; Kyeong-Ok Chang
Journal:  Eur J Med Chem       Date:  2012-02-11       Impact factor: 6.514

3.  Commensal Streptococcus mitis is a unique vector for oral mucosal vaccination.

Authors:  Nada Daifalla; Mark J Cayabyab; Emily Xie; Hyeun Bum Kim; Saul Tzipori; Philip Stashenko; Margaret Duncan; Antonio Campos-Neto
Journal:  Microbes Infect       Date:  2014-12-15       Impact factor: 2.700

Review 4.  Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

5.  Health and economic impact of rotavirus vaccination in GAVI-eligible countries.

Authors:  Sun-Young Kim; Steve Sweet; David Slichter; Sue J Goldie
Journal:  BMC Public Health       Date:  2010-05-14       Impact factor: 3.295

6.  The health and economic burden of rotavirus disease in Belgium.

Authors:  Joke Bilcke; Pierre Van Damme; Frank De Smet; Germaine Hanquet; Marc Van Ranst; Philippe Beutels
Journal:  Eur J Pediatr       Date:  2008-03-04       Impact factor: 3.183

7.  Cost-effectiveness of Rotavirus vaccination in Vietnam.

Authors:  Sun-Young Kim; Sue J Goldie; Joshua A Salomon
Journal:  BMC Public Health       Date:  2009-01-21       Impact factor: 3.295

8.  Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis.

Authors:  Johnie Rose; Rachael L Hawthorn; Brook Watts; Mendel E Singer
Journal:  BMJ       Date:  2009-09-25

9.  Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil.

Authors:  Ricardo Q Gurgel; Luis E Cuevas; Sarah C F Vieira; Vanessa C F Barros; Paula B Fontes; Eduardo F Salustino; Osamu Nakagomi; Toyoko Nakagomi; Winifred Dove; Nigel Cunliffe; Charles A Hart
Journal:  Emerg Infect Dis       Date:  2007-10       Impact factor: 6.883

10.  Recombinant outer capsid glycoprotein (VP7) of rotavirus expressed in insect cells induces neutralizing antibodies in rabbits.

Authors:  M Khodabandehloo; M Shamsi Shahrabadi; H Keyvani; B Bambai; Za Sadigh
Journal:  Iran J Public Health       Date:  2012-05-31       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.